PBR Nachrichten

 

The acquisition will provide access to Exl-111, a half-life extended, high-affinity anti-IgE antibody currently in Phase I clinical trials. Designed as an advanced extension of the established biology The post Novartis to acquire Excellergy for $2bn upfront appeared first on Pharmaceutical Business review....

The partnerships aim to apply AI within scientifically validated modelling workflows and define scalable, next-generation approaches throughout the drug development life cycle. The programmes will use Simulations Plus The post Simulations Plus and three pharma companies collaborate on AI-driven drug development appeared first on Pharmaceutical Business review....

The initiative will combine Cognito Therapeutics' investigational Spectris technology platform with the clinical infrastructure of Ochsner Health to explore innovative approaches to brain health across urban and rural The post Cognito Therapeutics and Ochsner partner for new brain health approaches appeared first on Pharmaceutical Business review....

Daiichi Sankyo will utilise Tempus' foundation models such as PRISM2, which integrates pathology images and clinical data to generate diagnostic and predictive insights. The partnership will combine Daiichi The post Daiichi Sankyo and Tempus AI collaborate on ADC clinical development appeared first on Pharmaceutical Business review....

Cardiac amyloidosis is a progressive condition where misfolded proteins accumulate in the heart muscle, often leading to heart failure. There are two main types of cardiac amyloidosis: wild-type The post Viz.ai and Alnylam to advance earlier identification of cardiac amyloidosis appeared first on Pharmaceutical Business review....

Under the agreement, Quotient will receive $20m upfront and could also earn up to $2.2bn through regulatory, development, and commercial milestone payments. Quotient's somatic genomics approach analyses naturally The post MSD and Quotient collaborate on IBD drug targets appeared first on Pharmaceutical Business review....

This collaboration is also aimed at expediting early-phase clinical trials and delivering new therapies to patients. It will leverage both organisations' expertise to advance healthcare innovation. Each partner The post Monash University and ClinChoice partner on new therapies development appeared first on Pharmaceutical Business review....

The agreement grants Sanofi worldwide rights to KT501, which is under evaluation in a first-in-human clinical trial for rheumatoid arthritis, focusing on tolerability, safety, pharmacodynamics, and pharmacokinetics. Under The post Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody appeared first on Pharmaceutical Business review....

This approval covers adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) who have carcinoma in situ (CIS), with or without papillary tumours. The authorisation follows a review The post ImmunityBio receives Macau approval for Anktiva combo therapy appeared first on Pharmaceutical Business review....

The FDA has approved Opdivo, along with doxorubicin, vinblastine, and dacarbazine (AVD) for adults and paediatric patients aged 12 years and above who have not previously been treated The post BMS secures FDA and EC approvals for Opdivo in Hodgkin Lymphoma appeared first on Pharmaceutical Business review....

Under the contract, Novartis will pay $2bn upfront and up to $1bn in milestones to acquire Synnovation Therapeutics' wholly owned subsidiary Pikavation Therapeutics, which holds SNV4818 and related The post Novartis to acquire SNV4818 from Synnovation appeared first on Pharmaceutical Business review....

The portfolio includes programmes targeting melanocortin 4 receptor (MC4R)-deficient genetic obesity, glucocerebrosidase 1 (GBA1)-driven Parkinson's disease, and Alpha-1 antitrypsin deficiency. The financing was co-led by Dimension and OrbiMed, The post Congruence secures $39.5m to advance small molecule correctors pipeline appeared first on Pharmaceutical Business review....

The company also secured an exclusive global licence for the development and commercialisation of AP306 with Alebund Pharmaceuticals, excluding Greater China. The funding will support the global development The post R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia appeared first on Pharmaceutical Business review....

This CRL stated that the application lacks substantial evidence of efficacy from adequate and well-controlled clinical investigations under the proposed conditions of use. The FDA noted inconsistencies in The post FDA issues CRL to Aldeyra's reproxalap drug application appeared first on Pharmaceutical Business review....

The regulatory action date for the humanised immunoglobulin G1, kappa (IgG1/k) monoclonal antibody sBLA review is anticipated by 29 October 2026. If approved, this would expand the therapy's The post FDA accepts Sun Pharma's Ilumya sBLA for psoriatic arthritis appeared first on Pharmaceutical Business review....

The move enables Sentynl to collaborate immediately with PRG S&T to advance clinical development of the molecule, which holds orphan drug status from the US Food and Drug The post Sentynl and PRG partner for Progerinin licence appeared first on Pharmaceutical Business review....

Supported by Enterprise Singapore, the initiative aims to enhance Biophytis' computational longevity platform and develop therapies for age-related diseases such as sarcopenia. The collaboration builds on Biophytis' ongoing The post Biophytis and LynxKite expand alliance to boost AI-driven drug discovery appeared first on Pharmaceutical Business review....

This marks Cosentyx as the first interleukin-17A (IL-17A) inhibitor approved for this population, offering a new biologic treatment option for paediatric patients with HS. HS is a chronic, The post Novartis wins FDA approval for Cosentyx to treat paediatric HS patients appeared first on Pharmaceutical Business review....

The partnership targets membrane proteins, intracellular protein–protein interactions and complex receptor systems through a new drug discovery platform. It aims to target disease areas where conventional small-molecule drug The post PRISM BioLab partners with Receptor.AI for molecule discovery appeared first on Pharmaceutical Business review....

The partnership aims to investigate ways to implement quantum computing solutions throughout the healthcare value chain, with a focus on resource allocation, research and development, and patient outcomes The post PsiQuantum and National Cancer Center Japan partner on quantum computing appeared first on Pharmaceutical Business review....